Pharmacielo Ltd represents a strong set of values and corporate philosophy in its operations. The company is committed to providing high-quality pharmaceutical-grade cannabis products to improve people's lives. Pharmacielo focuses on sustainability, innovation, and research to ensure the highest standards of cultivation and production. With a customer-centric approach, Pharmacielo strives to deliver value and satisfaction to its stakeholders. The company embraces transparency, integrity, and accountability, promoting ethical practices throughout its operations. Pharmacielo Ltd's dedication to excellence and its commitment to improving the well-being of individuals make it a leading player in the cannabis industry.

Pharmacielo Ltd is primarily present in Colombia, which serves as its main operating base and headquarters. With a focus on medicinal-grade cannabis, Pharmacielo is one of the leading companies in the country's rapidly growing cannabis industry. Additionally, the company has expanded its presence into other key regions such as Peru and Uruguay, further establishing its footprint in the Latin American market. As Pharmacielo continues to expand its operations, it remains dedicated to producing high-quality cannabis products and driving innovation in the global cannabis industry.

Pharmacielo Ltd has achieved several significant milestones. Firstly, the company obtained its medical cannabis cultivation license in Colombia, allowing it to cultivate and process cannabis plants. Additionally, Pharmacielo secured its Good Manufacturing Practices (GMP) certification, indicating adherence to quality and safety standards in pharmaceutical manufacturing. The company successfully exported its first commercial shipment of medicinal cannabis oil to Canada, marking a crucial step in expanding its international market presence. Furthermore, Pharmacielo received approval to cultivate and process cannabis in Portugal, enabling access to the European Union market. These achievements demonstrate Pharmacielo's commitment to becoming a global leader in the medicinal cannabis industry.

Pharmacielo Ltd is a leading global company in the cannabis industry. Founded in 2017, Pharmacielo has quickly gained prominence due to its strategic presence in Colombia, where it leverages the ideal climate and low-cost production advantages for cannabis cultivation. The company is focused on the cultivation, processing, and production of high-quality medicinal-grade cannabis oils and extracts. With a commitment to sustainability and innovation, Pharmacielo has established itself as a reliable producer and supplier of cannabis products, meeting the growing demand for medical cannabis globally. Emphasizing rigorous quality control and compliance with international standards, Pharmacielo Ltd strives to be a market leader in the rapidly expanding cannabis industry.

Some of the main competitors of Pharmacielo Ltd in the market include Canopy Growth Corporation, Aurora Cannabis Inc., and Aphria Inc.

Pharmacielo Ltd is primarily active in the cannabis industry.

The business model of Pharmacielo Ltd focuses on the cultivation, production, and distribution of medicinal-grade cannabis oil extracts and related products. As a leading global company in the cannabis industry, Pharmacielo Ltd aims to supply high-quality medicinal cannabis extracts to meet the increasing global demand. By leveraging their expertise in agriculture, pharmaceuticals, and innovation, Pharmacielo Ltd strives to deliver safe and effective cannabis-based medical solutions. With their vertically integrated operations, which include cultivation facilities, extraction labs, and distribution networks, the company is optimizing its supply chain to ensure consistent product quality, while also expanding its market reach to serve patients and healthcare providers across the globe.

Det Pharmacielo P/E-forhold er 0,68.

Pharmacielo KUV er 0,16.

AlleAktien Kvalitetsscore for Pharmacielo er 2/10.

Den forventede Pharmacielo omsætning er 118,49 mio. CAD.

Den forventede Pharmacielo indtjening er 28,36 mio. CAD.

Pharmacielo Ltd is a Canadian company specialized in the production and sale of medical cannabis. They operate in three different areas: cultivation, processing, and distribution of cannabis products. The company focuses on vertical integration to ensure a high-quality production chain. They have cultivation areas in Colombia, which provide ideal conditions due to the tropical climate. Continuous monitoring and inspections by both the company and government agencies secure the cultivation areas. The processing of the cannabis flowers and harvest takes place in a state-of-the-art facility certified according to international standards. Different technologies are employed to produce a high-quality end product. In the distribution sector, Pharmacielo offers various products based on medical cannabis, including oils, extracts, tinctures, suppositories, and capsules. The company's aim is to produce high-quality standardized products to ensure consistent product quality. Pharmacielo sells its products to end customers as well as wholesalers who further distribute the products. Pharmacielo's business model is based on a wholesale approach. This means that the company produces products at a wholesale level and sells them to other companies that resell the products under their own name or as the Pharmacielo brand. This relieves Pharmacielo from the distribution costs, which are taken over by the other companies. The advantage of the wholesale business model is that it allows the company to distribute its products on a broader scale while bearing only a fraction of the costs that individual sales would entail. To continue their success, Pharmacielo focuses on developing new products and expanding into new markets. The company relies on its expertise and knowledge in the production of medical cannabis. The aim is to expand the range of roll-on organic certified oils, tinctures, and capsules in order to better meet customer needs. Expanding the product offering is also an important step to differentiate from competitors and tap into new customers and markets. All in all, we can say that Pharmacielo is a profitable company that has established itself in the market for medical cannabis. They have a vertically integrated production chain that allows them to continuously produce high-quality products. The wholesale business model enables Pharmacielo to distribute its products widely and save costs. Expanding the product offering and entering new markets are the keys to the company's growth.

Pharmacielo udbetaler et udbytte på 0 CAD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Pharmacielo, eller selskabet udbetaler ikke udbytte.

ISIN'en for Pharmacielo er CA71716K1012.

WKN for Pharmacielo er A2PCAX.

Tickeren for Pharmacielo er PCLO.V.

I løbet af de sidste 12 måneder betalte Pharmacielo en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Pharmacielo sandsynligvis betale en dividende på 0 CAD.

Udbytteafkastet for Pharmacielo er i øjeblikket .

Pharmacielo betaler kvartalsvis udbytte. Dette uddeles i månederne .

Pharmacielo betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 CAD. Dette svarer til et dividendeafkast på 0 %.

Pharmacielo bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Pharmacielo fra den 24.9.2024 på 0 CAD, skulle du have haft aktien i din portefølje før ex-datoen den 24.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 24.9.2024.

I løbet af 2023 udbetalte Pharmacielo 0 CAD i form af dividender.

Udbytterne fra Pharmacielo udbetales i CAD.